Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

Sean Clouston In a recent study of 35 World Trade Center first responders in the Journal of Alzheimer’s Disease, lead author Sean Clouston, who is a Professor in the Department of Family, Population ...

Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test developed at the ...

Aside from the potential curse of long COVID, people who've had the SARS-CoV-2 virus may be more likely to develop high ...

In ‘Doctored’, Charles Piller, a science journalist, details how groupthink and dishonesty steered Alzheimer’s research off ...

A new study reveals that tau protein affects memory, while beta-amyloid disrupts emotions in Alzheimer’s disease. Using a novel mouse model, researchers found that both proteins interact to worsen ...

A new study suggests that getting more than six hours of good-quality sleep each night may help slow down or even prevent the ...

There is no cure. Between 1995 and 2021, around $42bn was poured into more than 1,000 clinical trials. Yet only a handful of ...

Researchers say CSF biomarker test correlates with the severity of cognitive decline, independent of other factors, including brain amyloid deposition.

AD neuropathology is due to the progressive deposition of extracellular amyloid-beta (Aβ) peptide and intracellular hyperphosphorylated tau protein. The accumulated Aβ forms amyloid plaques, while the ...